Please note that slides are for review only and not to be repurposed or published.

Keynote

Dr Bunn Jr
History, Major Findings and Lessons from LCMC

SESSION 1: Current and Future Application of Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

Module 1.1 — Dr Herbst
Emerging research information with the use of anti-PD-1/PD-L1 antibodies in patients with previously untreated metastatic NSCLC

Module 1.2 — Dr Neal
Practical assessment of PD-L1 status and integration of PD-L1 assays into clinical practice

Module 1.3 — Dr Rizvi
Current role of anti-PD-1/PD-L1 antibodies in patients with EGFR- or ALK-positive disease

Module 1.4 — Dr Pennell
Novel immunotherapeutic approaches; combination strategies with chemotherapy

SESSION 2: EGFR Mutation-Positive NSCLC

Module 2.1 — Dr Bunn
Molecular testing in clinical practice and the role of multiplex testing/next-generation sequencing (NGS)

Module 2.2 — Dr Shaw
Effect of EGFR variant on the selection of first-line systemic therapy

Module 2.3 — Dr Oxnard
Identification of acquired resistance: Detection of T790M and other secondary mutations in tissue, plasma and urine

Module 2.4 — Dr Herbst
Available efficacy and safety data with osimertinib; ongoing evaluation in the first-line setting; effectiveness in patients with CNS metastases

SESSION 3: EML4-ALK, ROS1, BRAF and Other Potentially Targetable Mutations

Module 3.1 — Dr Shaw
Optimal approach to ALK assessment; selection of first-line therapy for patients with ALK-rearranged or ROS1-positive NSCLC

Module 3.2 — Dr Oxnard
Approved and investigational TKIs for patients with ALK-positive disease progressing on first-line TKI therapy

Module 3.3 — Dr Bunn
Identification of and treatment for patients with BRAF-V600E tumor mutations

Module 3.4 — Dr Stinchcombe
Potential clinical benefits of and investigational opportunities associated with the identification of other oncogenic drivers (eg, HER2 and MET exon 14 skipping mutations, RET rearrangements)

SESSION 4: Management of Small Cell Lung Cancer, Mesothelioma and NSCLC with No Identified Targetable Mutations

Module 4.1 — Dr Rizvi
Emerging role of immune checkpoint inhibitors and ongoing clinical trials in malignant pleural mesothelioma (MPM)

Module 4.2 — Dr Stinchcombe
Current management and ongoing clinical trials in small cell lung cancer (SCLC)

Module 4.3 — Dr Socinski
Sequencing of systemic therapies and clinical trial options for patients with metastatic squamous cell carcinoma (SCC)

Module 4.4 — Dr Neal
Sequencing of systemic therapies and clinical trial options for patients with metastatic nonsquamous cell lung cancer

Module 4.5 — Dr Pennell
Is there a role for targeted therapy in the adjuvant or neoadjuvant setting?

SESSION 5: Quality and Value in the Management of Lung Cancer

Module 5.1 — Dr McAneny
The oncology home: Implications for the care of patients with lung cancer

Module 5.2 — Dr Lilenbaum
What clinicians can do about the cost of cancer care

SESSION 6: Lung Cancer Interdisciplinary Tumor Board

Module 6.1 — Dr Vallières
Prognostic molecular models in early-stage lung cancer

Module 6.2 — Dr Decker
Radiation therapy: Challenging clinical scenarios and related management issues

Module 6.3 — Dr Kelly
Adjuvant and neoadjuvant therapy

Module 6.4 — Dr Vallières
Controversies in the surgical management of lung cancer

Module 6.5 — Dr Decker
Recent therapeutic advances and novel trial concepts for patients with locally advanced NSCLC

Module 6.6 — Dr Kris
Optimal management of oligometastatic disease

SESSION 7: Practical Challenges in the Use of Immunotherapy

Module 7.1 — Dr Langer
Clinical complications associated with immunotherapy; immunotherapy in patients with a history of autoimmune disease

Module 7.2 — Dr Kris
Clinically relevant endpoints for checkpoint inhibitor trials; management approach for patients with prolonged progression-free survival: Is there a role for stopping therapy?

Module 7.3 — Dr Kelly
Clinical trials integrating immunotherapy and radiation therapy

Module 7.4 — Dr Langer
Immunotherapy in elderly patients and those with significant comorbidities